EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis

Simon G Royce, Cem Erdem, WeiYi Mao, Yan Wang, Mark P Del Borgo, Robert E Widdop iD, Chrishan S Samuel iD

Clinical Science · 2025

DOI: 10.1042/cs20245138 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Clinical Science, 2025. Verfasst von Simon G Royce und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Clayton, Victoria, 3800, Australia. Hauptthemen laut MEDLINE: Pyridones, Pulmonary Fibrosis, Receptor, Angiotensin, Type 2, Lung. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiotensin II AT2 receptor (AT2R) activation leads to significant anti-fibrotic and anti-inflammatory effects in diseased organs, which has led to clinical trial evaluation of the AT2R agonist, Compound 21 (C21), as a treatment for idiopathic pulmonary fibrosis (IPF). In this study, the anti-fibrotic effects of a more selective AT2R ligand, β-Pro7 angiotensin III (β-Pro7 Ang III), with >20,000-fold affinity for the AT2R over the AT1R, were compared with that of C21 or the currently used IPF medication, pirfenidone, in mice with bleomycin (BLM)-induced pulmonary fibrosis. Adult female BALB/c mice received a double intranasal instillation of BLM (20 mg/kg/day) seven days apart and were maintained until day 35, while control mice were instilled with saline (SAL) seven days apart and maintained for the same time period. Sub-groups of BLM-injured mice were then treated on day 28 with vehicle (SAL), C21 (0.3 mg/kg/day) or β-Pro7 Ang III (0.1 mg/kg/day) via seven-day subcutaneously implanted osmotic minipumps, or daily from days 28 to 35 via orally administered pirfenidone (100 mg/kg/day). At day-35 post-injury, measures of lung fibrosis and compliance were evaluated. Compared with their SAL-instilled counterparts, SAL-treated BLM-injured mice presented with a significantly increased lung Ashcroft score, Masson’s trichrome-stained and second harmonics generation-measured fibrosis, myofibroblast accumulation, and TGF-β1 expression, but reduced lung dynamic compliance at day-35 post-injury. While all treatments evaluated attenuated the BLM-induced lung myofibroblast accumulation and TGF-β1 expression, AT2R stimulation, but not pirfenidone, attenuated lung collagen deposition after seven days. β-Pro7 Ang III also significantly restored lung compliance and promoted collagen-degrading matrix metalloproteinase-2 activity. These findings highlighted the therapeutic value of selectively targeting the AT2R for treating IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridonesPulmonary FibrosisReceptor, Angiotensin, Type 2LungAntifibrotic AgentsAnimalsBleomycinFemaleMice, Inbred BALB CMiceLigandsDisease Models, AnimalImidazolesSulfonamidesThiophenes

Stichwörter der Autor:innen

AT2Rinterstitial collagenpulmonary fibrosistherapeuticsβ-Pro7 Ang III

Substanzen

BleomycinPyridonespirfenidoneReceptor, Angiotensin, Type 2compound 21Antifibrotic AgentsLigandsImidazolesSulfonamidesThiophenes

Autor:innen und Institutionen

  • Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Clayton, Victoria, 3800, Australia.

ORCID-Profile: Robert E Widdop, Chrishan S Samuel

Zitieren

APA

Royce, S. G., Erdem, C., Mao, W., Wang, Y., Del Borgo, M. P., Widdop, R. E., & Samuel, C. S. (2025). The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis. Clinical Science. https://doi.org/10.1042/cs20245138

Vancouver

Royce SG, Erdem C, Mao W, Wang Y, Del Borgo MP, Widdop RE, et al. The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis. Clinical Science. 2025. doi:10.1042/cs20245138

BibTeX
@article{Royce2025,
  author = {Royce, Simon G and Erdem, Cem and Mao, WeiYi and Wang, Yan and Del Borgo, Mark P and Widdop, Robert E and Samuel, Chrishan S},
  title = {The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis},
  journal = {Clinical Science},
  year = {2025},
  doi = {10.1042/cs20245138}
}
Kostenlos starten →